152 related articles for article (PubMed ID: 22399596)
1. Antiproliferative and antitumor effects of azacitidine against the human myelodysplastic syndrome cell line SKM-1.
Kimura S; Kuramoto K; Homan J; Naruoka H; Ego T; Nogawa M; Sugahara S; Naito H
Anticancer Res; 2012 Mar; 32(3):795-8. PubMed ID: 22399596
[TBL] [Abstract][Full Text] [Related]
2. Role of heme oxygenase-1 in demethylating effects on SKM-1 cells induced by decitabine.
Gao R; Ma D; Wang P; Sun J; Wang JS; Fang Q
Genet Mol Res; 2015 Dec; 14(4):17788-98. PubMed ID: 26782424
[TBL] [Abstract][Full Text] [Related]
3. Downregulation of HO-1 promoted apoptosis induced by decitabine via increasing p15INK4B promoter demethylation in myelodysplastic syndrome.
Ma D; Fang Q; Wang P; Gao R; Sun J; Li Y; Hu XY; Wang JS
Gene Ther; 2015 Apr; 22(4):287-96. PubMed ID: 25652099
[TBL] [Abstract][Full Text] [Related]
4. Effects of DNA methyltransferase inhibitors (DNMTIs) on MDS-derived cell lines.
Tsujioka T; Yokoi A; Uesugi M; Kishimoto M; Tochigi A; Suemori S; Tohyama Y; Tohyama K
Exp Hematol; 2013 Feb; 41(2):189-97. PubMed ID: 23085465
[TBL] [Abstract][Full Text] [Related]
5. In vivo effects of decitabine in myelodysplasia and acute myeloid leukemia: review of cytogenetic and molecular studies.
Hackanson B; Robbel C; Wijermans P; Lübbert M
Ann Hematol; 2005 Dec; 84 Suppl 1():32-8. PubMed ID: 16292549
[TBL] [Abstract][Full Text] [Related]
6. [Effect of decitabine combined with Trichostatin A on MDS cell line SKM-1 in vitro].
Yang L; Xu RR; Song GQ; Hang HM; Liu H; Jiang SH; Wang XF; Ding XS
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Aug; 16(4):819-23. PubMed ID: 18718068
[TBL] [Abstract][Full Text] [Related]
7. [Methylation of P15INK4B gene in patients with myelodysplastic syndromes and demethylating effects of drugs].
Ye XS; Liu T; Cui X; Meng WT; Xi YM
Sichuan Da Xue Xue Bao Yi Xue Ban; 2007 Jan; 38(1):57-9. PubMed ID: 17294728
[TBL] [Abstract][Full Text] [Related]
8. Characteristics of novel myeloid precursor cell line, PC-MDS, established from a bone marrow of the patient with therapy-related myelodysplastic syndrome.
Bogdanović G; Jurisić V; Kraguljac N; Mrdjanović J; Jakimov D; Krtolica K; Krajnović M; Magić Z; Stojiljković B; Andrijević L; Srdić T; Baltić M; Popović S
Leuk Res; 2007 Aug; 31(8):1097-1105. PubMed ID: 17350682
[TBL] [Abstract][Full Text] [Related]
9. Effects of azacitidine on matrix metalloproteinase-9 in acute myeloid leukemia and myelodysplasia.
Bernal T; Moncada-Pazos A; Soria-Valles C; Gutiérrez-Fernández A
Exp Hematol; 2013 Feb; 41(2):172-9. PubMed ID: 23085464
[TBL] [Abstract][Full Text] [Related]
10. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment.
Daskalakis M; Nguyen TT; Nguyen C; Guldberg P; Köhler G; Wijermans P; Jones PA; Lübbert M
Blood; 2002 Oct; 100(8):2957-64. PubMed ID: 12351408
[TBL] [Abstract][Full Text] [Related]
11. Human urine extract CDA-2 induces apoptosis of myelodysplastic syndrome-derived MUTZ-1 cells through the PI3K/Akt signaling pathway in a caspase-3-dependent manner.
Huang J; Yang M; Liu H; Jin J
Acta Pharmacol Sin; 2008 Aug; 29(8):951-64. PubMed ID: 18664328
[TBL] [Abstract][Full Text] [Related]
12. Effects of the combination of decitabine and homoharringtonine in SKM-1 and Kg-1a cells.
Geng S; Yao H; Weng J; Tong J; Huang X; Wu P; Deng C; Li M; Lu Z; Du X
Leuk Res; 2016 May; 44():17-24. PubMed ID: 26991610
[TBL] [Abstract][Full Text] [Related]
13. Clinical experience with decitabine in North American patients with myelodysplastic syndrome.
Yee KW; Jabbour E; Kantarjian HM; Giles FJ
Ann Hematol; 2005 Dec; 84 Suppl 1():18-24. PubMed ID: 16273408
[TBL] [Abstract][Full Text] [Related]
14. Characterization of DNA demethylation effects induced by 5-Aza-2'-deoxycytidine in patients with myelodysplastic syndrome.
Mund C; Hackanson B; Stresemann C; Lübbert M; Lyko F
Cancer Res; 2005 Aug; 65(16):7086-90. PubMed ID: 16103056
[TBL] [Abstract][Full Text] [Related]
15. Decitabine-Induced Changes in Human Myelodysplastic Syndrome Cell Line SKM-1 Are Mediated by FOXO3A Activation.
Zeng W; Dai H; Yan M; Cai X; Luo H; Ke M; Liu Z
J Immunol Res; 2017; 2017():4302320. PubMed ID: 29124072
[TBL] [Abstract][Full Text] [Related]
16. Hypomethylation and apoptosis in 5-azacytidine-treated myeloid cells.
Khan R; Schmidt-Mende J; Karimi M; Gogvadze V; Hassan M; Ekström TJ; Zhivotovsky B; Hellström-Lindberg E
Exp Hematol; 2008 Feb; 36(2):149-57. PubMed ID: 18206726
[TBL] [Abstract][Full Text] [Related]
17. Azacytidine and erlotinib exert synergistic effects against acute myeloid leukemia.
Lainey E; Wolfromm A; Marie N; Enot D; Scoazec M; Bouteloup C; Leroy C; Micol JB; De Botton S; Galluzzi L; Fenaux P; Kroemer G
Oncogene; 2013 Sep; 32(37):4331-42. PubMed ID: 23085751
[TBL] [Abstract][Full Text] [Related]
18. The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells.
Flotho C; Claus R; Batz C; Schneider M; Sandrock I; Ihde S; Plass C; Niemeyer CM; Lübbert M
Leukemia; 2009 Jun; 23(6):1019-28. PubMed ID: 19194470
[TBL] [Abstract][Full Text] [Related]
19. DNA methyltransferases as targets for cancer therapy.
Ghoshal K; Bai S
Drugs Today (Barc); 2007 Jun; 43(6):395-422. PubMed ID: 17612710
[TBL] [Abstract][Full Text] [Related]
20. Review of azacitidine trials in Intermediate-2-and High-risk myelodysplastic syndromes.
Fenaux P; Ades L
Leuk Res; 2009 Dec; 33 Suppl 2():S7-11. PubMed ID: 20004796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
